Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: A systematic review
Head & Neck2015Vol. 38(S1), pp. E2151–8
Citations Over TimeTop 1% of 2015 papers
Primož Strojan, Jan B. Vermorken, Jonathan J. Beitler, Nabil F. Saba, Missak Haigentz, Paolo Bossi, Francis P. Worden, Johannes A. Langendijk, Avraham Eisbruch, William M. Mendenhall, Anne W.M. Lee, Louis B. Harrison, Carol R. Bradford, Robert Smee, Carl E. Silver, Alessandra Rinaldo, Alfio Ferlito
Abstract
Results support the conclusion that the cumulative dose of cisplatin in concurrent chemoradiation protocols for HNSCC has a significant positive correlation with survival. © 2015 Wiley Periodicals, Inc. Head Neck 38: E2151-E2158, 2016.
Related Papers
- → The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin(2001)86 cited
- → Antitumor effect of radioactive cisplatin (191Pt) on nude mice(2001)37 cited
- Modulation of cisplatin resistance by 2'-deoxy-5-azacytidine in human ovarian tumor cell lines.(1994)
- → Treatment with Paclitaxel Alone Rather than Combination with Paclitaxel and Cisplatin May be Selective for Cisplatin-resistant Ovarian Carcinoma(2000)10 cited
- The Relationship between Expression of 1-Cys Peroxiredoxin and Resistance to Cisplatin in Epithelial Ovarian Cancer Cell Lines.(2006)